Dupixent Lawsuit Lawyer in Tennessee | T-cell Lymphoma (CTCL)

Last Updated: April 2026 | Written by Fob James IV, J.D., Mass Tort Attorney | Licensed in Tennessee, Alabama & Georgia | Fob James Law Firm

Helping Tennessee Patients Harmed by Dupixent (Dupilumab) Pursue Justice and Compensation

If you or a loved one in Tennessee was prescribed Dupixent (dupilumab) and later developed cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), mycosis fungoides, or Sézary syndrome, you may have grounds to file a Dupixent lawsuit against the drug’s manufacturers, Sanofi and Regeneron Pharmaceuticals.

Tennessee holds a unique and sobering place in this litigation: the first Dupixent wrongful death lawsuit in the United States was filed in Tennessee in October 2025 by Chandra Richardson, whose mother began using Dupixent in June 2024, was later diagnosed with T-cell lymphoma, and passed away in October 2024 just months after starting the drug.

At Fob James Law Firm, our attorneys are licensed in Tennessee, Alabama, and Georgia and represent Dupixent injury clients across Nashville, Memphis, Knoxville, Chattanooga, and throughout the state. We have recovered over $100 million for more than 1,000 clients in defective drug and injury cases nationwide. All Dupixent cases are handled on a contingency fee basis — you pay nothing unless we win.

Quick Answers: Dupixent Lawsuit Tennessee

What Is Dupixent, and Why Are Tennessee Patients Filing Lawsuits?

Dupixent (dupilumab) is an injectable biologic drug manufactured by Sanofi and Regeneron Pharmaceuticals. FDA-approved since 2017, Dupixent is now indicated for:

• Moderate-to-severe atopic dermatitis (eczema)
• Certain types of asthma
• Chronic rhinosinusitis with nasal polyps
• Eosinophilic esophagitis (EoE)
• Prurigo nodularis
• Chronic obstructive pulmonary disease (COPD)

Dupixent generated $18.3 billion in global sales in 2025, making it one of the most commercially successful biologic drugs in history. Plaintiffs in Dupixent lawsuits across Tennessee and the country allege that Sanofi and Regeneron prioritized those revenues over patient safety, specifically by failing to disclose a serious and growing body of evidence linking Dupixent to T-cell lymphoma.

The central allegation: the manufacturers knew or should have known that Dupixent could cause, unmask, or accelerate cutaneous T-cell lymphoma in certain patients — and they never warned Tennessee doctors or patients. As of April 2026, the word “lymphoma” does not appear anywhere in Dupixent’s FDA-approved prescribing label.

Tennessee and the First Dupixent Wrongful Death Lawsuit in America

Tennessee earned a grim distinction in October 2025: it was the site of the first Dupixent wrongful death lawsuit filed anywhere in the United States. The case was brought by Chandra Richardson on behalf of her mother’s estate.

According to the complaint, Richardson’s mother began receiving Dupixent injections in June 2024 for atopic dermatitis. She was subsequently diagnosed with T-cell lymphoma. The disease progressed rapidly, and she passed away in October 2024 — approximately four months after starting Dupixent. The lawsuit alleges that Sanofi and Regeneron knew or should have known about the link between Dupixent and T-cell lymphoma, and that their failure to warn caused the delayed diagnosis and death.

This case is significant for Tennessee clients for two reasons. First, it establishes that wrongful death claims based on Dupixent-linked lymphoma are viable and are being litigated right now rather than in the future. Second, it puts Tennessee at the forefront of this litigation, with courts and attorneys in the state already familiar with these facts.

Cancers Linked to Dupixent: CTCL, PTCL, Mycosis Fungoides, and Sézary Syndrome

Two primary categories of T-cell malignancy have been associated with Dupixent use in published research and active litigation:

Cutaneous T-Cell Lymphoma (CTCL)

CTCL is a rare form of non-Hodgkin lymphoma in which malignant T-cells migrate to and accumulate in the skin. In early stages, CTCL is nearly indistinguishable from atopic dermatitis, which is the very condition Dupixent is prescribed to treat. When Dupixent suppresses the visible skin inflammation, the cancer’s symptoms are masked while the disease continues to advance. By the time the true diagnosis is made, patients are frequently at an advanced stage where treatment is more aggressive, more expensive, and outcomes are worse.

The most common CTCL subtypes seen in Dupixent litigation:

• Mycosis Fungoides — the most prevalent form, presenting as flat, scaly patches that mimic eczema and partially respond to topical steroids
• Sézary Syndrome — an aggressive systemic form affecting the blood and lymphatic system, causing widespread redness and severe immune dysfunction
• Primary cutaneous CD30+ T-cell lymphoproliferative disorders

Peripheral T-Cell Lymphoma (PTCL)

The first Tennessee Dupixent wrongful death case involved T-cell lymphoma, a disease that includes both CTCL and peripheral T-cell lymphoma (PTCL). Filed lawsuits in other states have also documented PTCL following Dupixent use, including a 2026 Illinois case where a patient developed PTCL after just five Dupixent injections. Our Tennessee legal team evaluates both CTCL and PTCL claims.

Why Dupixent Makes T-Cell Lymphoma So Dangerous to Diagnose

The most dangerous aspect of the Dupixent-CTCL connection is that early-stage cutaneous T-cell lymphoma and atopic dermatitis can look clinically identical, even under biopsy in some cases. Both conditions present with:

• Red, inflamed, itchy skin patches
• Scaly or crusted plaques
• Thickened, leathery skin texture (lichenification)
• Symptoms that flare and subside cyclically
• Partial or temporary response to topical corticosteroids

When a Tennessee patient with undiagnosed CTCL receives Dupixent, the drug reduces visible skin inflammation, and this improvement appears to confirm the eczema diagnosis. Both the patient and the prescribing dermatologist interpret the improvement as the drug working. But beneath the surface, the cancer continues to progress. By the time the disease breaks through the suppression — often with dramatically worsened or atypical symptoms — the patient is already at a more advanced stage.

This is not a theoretical concern. The Tennessee wrongful death case describes exactly this pattern: a patient diagnosed with eczema, treated with Dupixent, rapid disease progression, and death within months of starting the drug. Plaintiffs allege that Sanofi and Regeneron had a duty to warn against this precise sequence of events, and they failed to do so.

Scientific Evidence Supporting Tennessee Dupixent Lawsuits

Tennessee Dupixent lawsuits rest on a substantial and growing body of peer-reviewed medical research:

Major Database Studies

• JAMA Dermatology (April 2024): Study of 19,612 atopic dermatitis patients found Dupixent users were 4.1x more likely to develop CTCL (OR 4.1, 95% CI 2.1–8.2) vs. non-users. Most diagnoses occurred more than one year after starting Dupixent.
• Dermatologic Therapy (August 2024): TriNetX analysis of 1.18 million AD patients found 4.6x higher relative risk of CTCL (RR 4.6, 95% CI 2.5–8.6). Risk was highest in patients over 60 and within the first year of treatment.
• Journal of Allergy and Clinical Immunology (January 2025): FAERS and RNA-Seq analysis. Dupixent had a 30x higher CTCL reporting rate vs. all other medications. Proposed mechanism: IL-13 pathway suppression accelerates malignant T-cell proliferation.
• European Respiratory Journal (June 2025): Asthma patients on Dupixent — not eczema patients — had 4.5x higher CTCL risk vs. standard inhaler therapy. The risk signal extends beyond eczema to other Dupixent indications.

FDA Adverse Event Data and Regulatory Actions

• March 2025: FDA formally announced an investigation into Dupixent’s link to CTCL and placed Dupixent on a watch list for medications with potentially serious risks.
• May 2025: FAERS analysis — 181,575 total Dupixent adverse event reports. CTCL-specific reporting rate was approximately 30x higher than for all other drugs in the database.
• October 2025: FAERS contained nearly 300 lymphoma reports linked to Dupixent, including more than 138 CTCL cases.
• April 2026: The word ‘lymphoma’ still does not appear in Dupixent’s FDA-approved prescribing label. No recall has been issued. The failure-to-warn claim remains fully intact.

Case Series and Clinical Reports

• JAAD Case Reports (2022): Seven patients with severe atopic dermatitis developed or experienced worsening CTCL after starting Dupixent. Average time to CTCL diagnosis: 7.8 months.
• International Journal of Dermatology (2023): Systematic review of 18 cases — all had more than 50% body surface involvement before diagnosis; advanced stages (III/IV) were common.
• Blood Journal (November 2023): 25 patients at Memorial Sloan Kettering Cancer Center. Median time from Dupixent initiation to CTCL diagnosis: 10 months. Disease progression was often accelerated.

Warning Signs of Dupixent-Associated Lymphoma in Tennessee Patients

If you are taking Dupixent and develop any of the following symptoms, contact your physician immediately. Do not stop your medication without medical guidance. Specifically request evaluation for lymphoma:

• New or worsening skin patches, plaques, or nodules that are scaly, itchy, or burning
• Persistent red or purple skin lesions that do not respond to treatment as expected for eczema
• Thickened or tumorous skin areas, particularly on sun-protected body surfaces
• Swollen lymph nodes in the neck, armpits, or groin
• Unexplained weight loss, persistent night sweats, or recurring fevers — known as ‘B symptoms’
• Eczema that initially improves on Dupixent then later worsens or behaves atypically
• A dermatologist who describes your condition as ‘resistant’ or ‘unusual’ eczema

Dupixent Lawsuit Litigation Timeline — Updated April 2026

Legal Claims in a Tennessee Dupixent Lawsuit

Tennessee Dupixent lawsuits are governed by the Tennessee Products Liability Act (Tenn. Code §§ 29-28-101 et seq.), which allows claims against manufacturers for defective products that cause injury. The primary theories include:

• Failure to warn — Sanofi and Regeneron failed to warn Tennessee patients and prescribers about the risk of CTCL and PTCL, despite a substantial body of adverse event data and peer-reviewed research establishing the association.
• Defective product — Dupixent is defective because it lacked adequate instructions or warnings about the risk of T-cell lymphoma, as required under Tenn. Code § 29-28-105.
• Negligence — the manufacturers breached their duty of care by failing to update the Dupixent label, implement prescreening protocols, or provide stop-and-investigate guidance to prescribers.
• Aggressive marketing despite known risk — Sanofi and Regeneron marketed Dupixent to capture $18+ billion in annual revenue while suppressing or ignoring emerging cancer safety signals.
• Wrongful death — in cases where a Tennessee patient died from CTCL or PTCL linked to Dupixent, surviving family members may pursue wrongful death claims under Tenn. Code § 20-5-106.

Under Tennessee product liability law, a manufacturer is liable if it knew or should have known that its product posed a risk of harm that was not adequately communicated to users. The volume of FAERS adverse event reports, peer-reviewed studies, and FDA regulatory actions available to Sanofi and Regeneron prior to the first Tennessee wrongful death case provides a strong evidentiary foundation for these claims.

Who Can File a Dupixent Lawsuit in Tennessee?

You may be eligible to file a Tennessee Dupixent lawsuit if:

• You were prescribed Dupixent for eczema, asthma, nasal polyps, EoE, COPD, or another approved indication.
• You were later diagnosed with CTCL, PTCL, mycosis fungoides, Sézary syndrome, or another T-cell or NK-cell malignancy.
• Your cancer diagnosis occurred during or after Dupixent treatment, or your pre-existing but undiagnosed CTCL was allegedly accelerated or masked by Dupixent.
• You have medical records — including pathology reports — documenting both your Dupixent use and your cancer diagnosis.
• You can file within Tennessee’s one-year statute of limitations (see below).

Tennessee family members of patients who died from T-cell lymphoma linked to Dupixent may also have standing to bring wrongful death claims under Tenn. Code § 20-5-106. The first such case in the country was filed in Tennessee. Contact our firm immediately if a loved one has died.

What Compensation Can Tennessee Dupixent Victims Recover?

Under Tennessee law, victims of Dupixent-related cancer injuries may be entitled to:

• Medical expenses — past treatment costs (chemotherapy, radiation, stem cell transplants) and all projected future care
• Lost wages and loss of future earning capacity
• Pain and suffering
• Emotional distress and psychological harm
• Loss of enjoyment of life
• Wrongful death damages — including funeral and burial costs, lost income, and loss of consortium for surviving family members

Tennessee does not cap compensatory damages in product liability cases. Each case is evaluated based on the severity of injury, strength of medical evidence, timing of Dupixent use, and other facts specific to your case. Our attorneys provide a detailed damages analysis during your free case review.

Tennessee Statute of Limitations for Dupixent Claims — Act Within One Year

The discovery rule in Tennessee means the one-year clock starts running when you knew or reasonably should have known both (1) that you were injured and (2) that the injury was connected to Dupixent. For many Tennessee patients, that date is March 2025 — when the FDA formally announced its investigation into Dupixent’s link to CTCL and the news became widely reported. If the FDA announcement triggered your awareness, your deadline may be as early as March 2026.

However, this analysis is highly fact-specific. The discovery date depends on your individual medical history, when you received your diagnosis, and when you had reason to connect your cancer to Dupixent. The only way to know for certain is to speak with a Tennessee Dupixent attorney now. Call 866-837-1010 to learn more.

Steps to Take If You Are a Tennessee Dupixent Patient With a Cancer Diagnosis

1. Consult your physician before stopping Dupixent — do not discontinue without medical supervision.
2. Request complete copies of your medical records, including dermatology notes, pathology and biopsy reports, and all oncology treatment records.
3. Document your Dupixent timeline precisely: start date, dosage and frequency, when symptoms changed, and the exact date of your cancer diagnosis.
4. Preserve all prescription records, pharmacy receipts, and insurance records related to Dupixent.
5. Call Fob James Law Firm at 866-837-1010 immediately and do not wait. Tennessee’s one-year deadline is unforgiving.
6. Do not provide recorded statements to Sanofi, Regeneron, or their representatives without first speaking to a Tennessee Dupixent attorney.

Why Choose Fob James Law Firm for Your Tennessee Dupixent Lawsuit?

• Tennessee-licensed attorneys — Fob James IV holds an active Tennessee bar license, meaning no need for local co-counsel in most matters
• First-hand knowledge of Tennessee wrongful death law — we understand Tenn. Code § 20-5-106 and how to maximize recovery for Tennessee families
• Over $100 million recovered for 1,000+ clients in defective drug and injury litigation across 48 states
• Access to board-certified dermatologists, oncologists, and immunologists who review medical records and provide expert testimony
• National mass tort resources — the infrastructure needed to take on Sanofi and Regeneron in federal court
• Contingency fee only — no upfront costs, no hourly fees, no out-of-pocket expenses unless we win
• Tennessee cities served: Nashville, Memphis, Knoxville, Chattanooga, Clarksville, Murfreesboro, Franklin, Johnson City, Kingsport, and all surrounding communities

Frequently Asked Questions About Dupixent Lawsuits in Tennessee

Is there a Dupixent recall in 2026?

No. As of April 2026, the FDA has not recalled Dupixent. The FDA formally announced an investigation into the drug’s link to CTCL in March 2025 and continues reviewing adverse event reports. Dupixent remains on the market with no cancer warning anywhere in its prescribing label.

What cancers are linked to Dupixent?

The primary cancers linked to Dupixent are cutaneous T-cell lymphoma (CTCL) — including mycosis fungoides and Sézary syndrome — and peripheral T-cell lymphoma (PTCL). The first Dupixent wrongful death lawsuit in the United States, filed in Tennessee in October 2025, involved T-cell lymphoma.

How long do I have to file a Dupixent lawsuit in Tennessee?

One year. Under Tenn. Code § 28-3-104, Tennessee’s statute of limitations for product liability and personal injury claims is one year from the date of injury or discovery of the connection to Dupixent. This is shorter than any other state commonly involved in this litigation. For patients who first learned of the Dupixent-CTCL link through the FDA’s March 2025 announcement, the deadline may be as early as March 2026. Call 866-837-1010 now.

Was the first Dupixent wrongful death lawsuit filed in Tennessee?

Yes. In October 2025, Chandra Richardson filed the first Dupixent wrongful death lawsuit in the United States in Tennessee. Her mother began using Dupixent in June 2024 for eczema, was later diagnosed with T-cell lymphoma, and died in October 2024. The lawsuit alleges that Sanofi and Regeneron knew about the CTCL risk and failed to warn patients and doctors.

Is there a Dupixent class action or MDL?

Dupixent cases are not class actions. In February 2026, a motion was filed before the JPML to consolidate all federal Dupixent CTCL cases into a single MDL, with the Northern District of Georgia proposed as the venue. Approximately 18 federal cases are pending as of late March 2026. A JPML ruling is expected mid-2026. Critically, MDL formation does not stop Tennessee’s one-year state-law deadline from running.

Does filing in federal court toll Tennessee’s statute of limitations?

Not automatically. Filing a federal claim in an anticipated MDL does not toll Tennessee’s state-law one-year limitations period under Tenn. Code § 28-3-104. If you have Tennessee state-law claims under the Products Liability Act, those deadlines run independently. You must consult a Tennessee-licensed Dupixent attorney immediately to protect all available claims.

Can my family file a wrongful death claim if a loved one died from Dupixent-linked lymphoma in Tennessee?

Yes. Under Tenn. Code § 20-5-106, the personal representative of the deceased patient’s estate may bring a wrongful death action against Sanofi and Regeneron. Surviving family members — spouses, children, parents — may recover damages for pain and suffering, medical expenses, lost income, and the value of the life lost. The first such lawsuit in the country was filed in Tennessee. Contact us immediately if a family member has died.

I was prescribed Dupixent for asthma, not eczema. Can I still file a Tennessee lawsuit?

Potentially yes. A June 2025 study in the European Respiratory Journal found that asthma patients on Dupixent had a 4.5x higher risk of CTCL compared to patients on standard asthma medications. The cancer risk signal is not limited to eczema patients. Tennessee asthma patients who developed CTCL or PTCL should contact us for a case review.

Is the Dupixent label defective under Tennessee law?

Plaintiffs argue yes. Under the Tennessee Products Liability Act (Tenn. Code § 29-28-105), a product is defective if it fails to include adequate warnings of known or reasonably discoverable risks. As of April 2026, Dupixent’s label contains no warning about CTCL, PTCL, mycosis fungoides, or Sézary syndrome. The word ‘lymphoma’ does not appear anywhere in the prescribing information, despite hundreds of FDA adverse event reports and multiple peer-reviewed studies. See also our Alabama Dupixent lawsuit page and Georgia Dupixent lawsuit page for additional background on the failure-to-warn theory.

How much does it cost to hire a Tennessee Dupixent lawyer?

Nothing upfront. Fob James Law Firm handles all Dupixent cases on a contingency fee basis. You owe nothing unless we win your case. There are no hourly fees, retainers, or out-of-pocket litigation costs to get started.

How do I start a Dupixent claim in Tennessee?

Call Fob James Law Firm at 866-837-1010 now. Given Tennessee’s one-year limitation period, delay is the most dangerous thing you can do. You can also complete our online case evaluation form at callfob.com/contact. Our Tennessee-licensed legal team will review your case, explain your rights, and protect your deadline immediately.

Contact a Tennessee Dupixent Lawsuit Lawyer Today — Free Consultation

If you or a family member in Tennessee developed T-cell lymphoma, CTCL, PTCL, mycosis fungoides, or Sézary syndrome after taking Dupixent — or if a loved one died from Dupixent-linked lymphoma — do not wait another day.

Call Fob James Law Firm at 866-837-1010 or complete our online form at callfob.com/contact for a free, confidential Tennessee case evaluation. Our Tennessee-licensed attorneys serve clients across Nashville, Memphis, Knoxville, Chattanooga, Clarksville, Murfreesboro, Franklin, Johnson City, and every surrounding community.

Our Dupixent lawsuit lawyers are ready to fight for your rights and hold Sanofi and Regeneron accountable.